Acurx shareholders approve warrant exercise and authorized share increase at special meeting

Acurx Pharmaceuticals, Inc.

Proposal 1 (warrant exercise for Nasdaq compliance): 8,816,581 for, 602,155 against, 9,823,429 broker non-votes.
Proposal 2 (authorized share increase 200M to 250M): 16,476,460 for, 2,526,119 against, 363,000 abstentions.
Proposal 3 (adjournment) approved: 16,538,163 for, 2,271,234 against, 556,182 abstentions.
Quorum: 19,365,579 shares (63.44%) of 30,524,540 outstanding shares represented.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.